Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Gingrich ethics probe

This article was originally published in The Gray Sheet

Executive Summary

Gingrich ethics probe: House Committee on Standards of Official Conduct, which is investigating charges of ethics violations involving House Speaker Newt Gingrich (R-Ga.), dismisses "the allegation of improper intervention with the Executive branch for a donor to the Progress and Freedom Foundation (Direct Access Diagnostics)," the committee said in a Dec. 6 letter to the speaker. Elliott Millenson, former CEO and president of the Johnson & Johnson subsidiary, testified before the committee Nov. 29. He reportedly discussed contributions that he, Direct Access and J&J made to the Progress and Freedom Foundation -- a conservative think tank with close ties to the speaker -- and a possible link between the contributions and Gingrich's query to the White House on the status of DAD's Confide home-use HIV specimen collection kit...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005174

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel